AI-Driven Radiotherapy: The ARCHERY Trial Could Close the Global Cancer Care Gap
A breakthrough in artificial intelligence is poised to transform how life-saving radiotherapy is delivered, potentially saving millions of lives by bridging the massive gap in global cancer care. Results from the international ARCHERY trial, led by researchers at University College London (UCL) and the London School of Hygiene & Tropical Medicine (LSHTM), demonstrate that AI technology can plan complex radiotherapy treatments with a high degree of precision, even in resource-limited settings.
The findings, presented at the European Society for Radiotherapy and Oncology (ESTRO 2026) congress in Stockholm, offer a scalable solution to one of oncology’s most pressing challenges: the shortage of specialized professionals required to plan radiation treatments.
The Global Crisis in Cancer Treatment Access
The disparity in cancer survival rates is often a matter of geography rather than biology. For cervical cancer, the statistics are stark: 94% of deaths occur in low- and middle-income countries, with approximately 350,000 women dying from the disease in 2022 alone. While radiotherapy is the primary curative treatment, access remains critically low. In low-income nations, only 10% of patients who require radiotherapy actually receive it, compared to 40% in middle-income countries.
A major bottleneck in this process is the complexity of radiotherapy planning. Traditionally, this requires an oncologist to outline tumors and healthy tissue on CT scans, followed by a physicist determining the optimal size, shape, and position of radiation beams. This meticulous process can take specialized staff days or even weeks to complete.
The ARCHERY Trial: Precision at Scale
The ARCHERY trial addressed this bottleneck by testing AI-based software across diverse clinical environments. Conducted at hospitals in India, South Africa, Jordan, and Malaysia, the study involved more than 1,000 patients diagnosed with three primary cancer types: cervical, prostate, and head and neck cancers.
The trial evaluated whether the AI could match the international “best-practice” standards typically set by human oncologists and physicists. The results were highly encouraging:
- Cervical Cancer: The AI technology achieved a high standard of planning in more than 95% of cases.
- Prostate Cancer: The technology met high-standard requirements in 85% of cases, a level considered suitable for routine clinical use.
- Head and Neck Cancer: Data for this category is expected to be released later this year.
Professor Ajay Aggarwal, chief investigator from LSHTM and Guy’s & St Thomas’ NHS Trust, noted that these results support the routine use of AI in hospitals globally. He emphasized that this technology could directly support the World Health Organization’s cervical cancer elimination initiative by reducing waiting times and expanding access.
Transforming Clinical Workflows: From Weeks to Hours
The most significant impact of this AI technology is its ability to compress the treatment planning timeline. By automatically identifying target structures and determining optimal radiation beam configurations, the software reduces a process that traditionally takes weeks to just over one hour.
Professor Mahesh Parmar, Director of UCL’s Institute of Clinical Trials, highlighted the scale of the opportunity. “Radiotherapy is a core cancer treatment, helping to cure 40% of cancer cases. Yet millions of people around the world do not have access to it. If they did, we could save more than a million lives a year,” Parmar stated.
Unlike many previous AI studies that were small-scale or limited to high-income countries, the ARCHERY trial provided rigorous evidence from diverse settings, proving that AI can be effectively implemented where the need is often greatest.
Key Takeaways: AI in Oncology
| Feature | Traditional Planning | AI-Assisted Planning (ARCHERY) |
|---|---|---|
| Time Requirement | Days to Weeks | Approximately 1 hour |
| Cervical Cancer Accuracy | Human-standard baseline | >95% high-standard achievement |
| Primary Benefit | High precision, high labor | Rapid delivery, increased accessibility |
| Global Utility | Limited by specialist availability | Scalable to low-resource settings |
The Future of Radiotherapy
While the ARCHERY trial marks a significant milestone, the integration of AI into oncology is an evolving frontier. Experts suggest that while AI can optimize efficiency and save hospital resources, its primary value lies in its ability to democratize high-quality care. As the technology matures, it holds the potential to ensure that a patient’s ability to survive cancer is no longer determined by their proximity to a specialized medical center.